European Journal of Biomedical and Pharmaceutical sciences: 3 (9): 147-152, 2016.
تم نشر البحث في المجلة الاوربية لعلوم الطبية والصيدلانية لسنة 2016 أن البحث يقوم بدراسة وتقدير وتشخيص جديد بأستخدام النيوكلوسايد وخاصة السيدويوردين في الدم وفي اللعاب للمرضى المصابين لمرض السرطان الاولي في الدماغ وهذه الطريقة التشخيصية تعتبر من الطرق الجديدة في التشخيص الطبي وبأستخدام تقنية
High Performance Liquid Chromatography (HPLC)
لقد تم نشر خمسة بحوث لسنة 2015 - 2016
Abstract Background: Pseudouridine is a modified nucleoside derived from the degradation of some species Ribonucleic acid (RNA), primarily transfer RNA the level of which is elevated in biological fluids of tumor bearing subjects. This study was first done to measure Pseudouridine in serum and saliva of primary brain tumor patients.
Aim of Study: A prospective study designed to measure the levels of pseudouridine in serum and saliva of primary brain tumor (PBT) patients.
Materials and Methods: This study had been conducted between November 2014 and October 2015. Employed in this study, in addition to the forty normal subjects used as controls, there were one hundred seven patients diagnosed clinically and histologically as having PBT. Their ages were between 2-75 years, (mean 35, the standard SD ± 19), 56 were males (52.33%), and 51 were females (47.67%). The most affected age group was 31-40 years (17.75%), 89% of the patients were under the age of 60 years. Histological typing: 44 gliomas and 32 meningiomas.
Results: Mean levels of pseudouridine in serum and saliva of PBT patients, were significantly higher (p < 0.01) than its levels in normal.
Conclusions and recommendations: Levels of pseudouridine in serum and saliva can be an extra tool in the investigation of PBT patients; however, both the specificity and sensitivity need to be ascertained.